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Background: The molecular mechanisms responsible for angiogenesis and abnormal expression of angiogenic
factors in gastric cancer, including vascular endothelial growth factor (VEGF), remain unclear. The histone
demethylase retinoblastoma binding protein 2 (RBP2) is involved in gastric tumorgenesis by inhibiting the
expression of cyclin-dependent kinase inhibitors (CDKIs).
Methods: The expression of RBP2, VEGF, CD31, CD34 and Ki67 was assessed in 30 human gastric cancer samples
and normal control samples. We used quantitative RT-PCR, western blot analysis, ELISA, tube-formation assay and
colony-formation assay to characterize the change in VEGF expression and associated biological activities induced
by RBP2 silencing or overexpression. Luciferase assay and ChIP were used to explore the direct regulation of RBP2
on the promoter activity of VEGF. Nude mice and RBP2-targeted mutant mice were used to detect the role of RBP2
in VEGF expression and angiogenesis in vivo.
Results: RBP2 and VEGF were both overexpressed in human gastric cancer tissue, with greater microvessel density
(MVD) and cell proliferation as compared with normal tissue. In gastric epithelial cell lines, RBP2 overexpression
significantly promoted the expression of VEGF and the growth and angiogenesis of the cells, while RBP2
knockdown had the reverse effect. RBP2 directly bound to the promoter of VEGF to regulate its expression by
histone H3K4 demethylation. The subcutis of nude mice transfected with BGC-823 cells with RBP2 knockdown showed
reduced VEGF expression and MVD, with reduced carcinogenesis and cell proliferation. In addition, the gastric epithelia
of RBP2 mutant mice with increased H3K4 trimethylation showed reduced VEGF expression and MVD.
Conclusions: The promotion of gastric tumorigenesis by RBP2 was significantly associated with transactivation of
VEGF expression and elevated angiogenesis. Overexpression of RBP2 and activation of VEGF might play important
roles in human gastric cancer development and progression.
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Gastric cancer is an important health problem around the
world and the cause of 12% of all cancer-related deaths
each year [1,2], especially in China, which accounts for
42% of the global total cases [3]. Carcinogenesis is a multi-
step process involving the transformation, survival, prolif-
eration, invasion, angiogenesis, and metastasis of tumor.
During this process, the accumulation of genetic and epi-
genetic alterations leads to progressive transformation [4].* Correspondence: zengjp@sdu.edu.cn
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nosis and treatment.
Angiogenesis is a process of neovascular formation from
pre-existing blood vessels, which consists of sequential
steps for vascular destabilization, angiogenic sprouting,
lumen formation and vascular stabilization. Induction of
angiogenesis represents one of the major hallmarks of
cancer [5]. Vascular endothelial growth factor (VEGF) is a
key mediator in the neovascularization of cancers [6].
Through a VEGF-induced signaling pathway, such as
PI3K-AKT, JAK2-STAT5 and ERK1/2, VEGF is involved
in angiogenesis and proliferation [7]. VEGF overexpres-
sion involves abnormal expression of growth factors andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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VEGF expression. VEGF expression is suppressed by pro-
moter hypermethylation [9]. MiR-125a and miR-126 can
inhibit its expression [10,11]. To better understand the
mechanism of angiogenesis, the regulation of VEGF ex-
pression is a key point.
Histone modification plays an important role in car-
cinogenesis, including angiogenesis [5,12]. For example,
histone methylase MLL1 has critical roles in tumor
growth and angiogenesis [13]. HDAC3 acts as a negative
regulator of angiogenesis [14]. Retinoblastoma binding
protein 2 (RBP2), a newly found histone demethylase
for H3 lysine 4 (H3K4) trimethylation and dimethyla-
tion, is involved in gastric tumorgenesis with its epigen-
etic inhibition of cyclin-dependent kinase inhibitors
(CDKIs) [15]. We also found a high expression of RBP2
in hepatocellular carcinoma and its inhibition triggered
cell senescence [16]. Others also suggested that loss of
RBP2 suppresses tumorigenesis in mice lacking Rb1 or
Men1 [17].
In the present study, we sought to determine the po-
tential role of RBP2 in human gastric cancer angiogen-
esis via the regulation of VEGF and the underlying
mechanisms in vivo and in vitro.
Results
Association of RBP2 overexpression with increased VEGF
expression and MVD in human gastric cancer
As compared with normal human tissues, gastric cancer
specimens showed overexpression of RBP2 and VEGF
mRNA and the correlation of mRNA expression, which
supports the role of RBP2 and VEGF in tumorgenesis
and their co-expression in vivo (Figure 1A, B and C). By
Immunohistochemistry (IHC) we observed high RBP2
expression in 14 cases (70%) and low expression in 6
cases (30%). At the same sites, we observed strong VEGF
expression in 15 cases (75%) and weak expression in 5
cases (25%). In addition, we observed high MVD in 15
cases (75%) and low MVD in 5 cases (25%) as seen by
positive CD31 and CD34 staining (Figure 1F). The ex-
pression pattern of RBP2 was consistent with that of
VEGF and MVD status. The marker of cell proliferation,
Ki67, was also overexpressed in human gastric cancer
specimens (Figure 1D, E). This clinical evidence supports
the association of RBP2 and VEGF expression and in-
creased angiogenesis in gastric cancer. RBP2 or VEGF
expression was associated with tumor size but not age,
gender, specimen histology or differentiation (Additional
file 1: Table S1).
Regulation of VEGF expression by RBP2 in human gastric
cancer cells and RBP2-targeted mutant mice
To obtain direct evidence of whether RBP2 regulated the
expression of VEGF and was involved in the angiogenesisof gastric cancer, we transfected RBP2 expression vec-
tor and siRNA into BGC-823, SGC-7901 and GES-1
cells. Cells transfected with RBP2 siRNA showed de-
creased mRNA and protein levels of VEGF as com-
pared with control siRNA transfection (Figure 2A-D).
As well, histone H3K4 tri- and dimethylation was in-
creased with RBP2 silencing (Figure 2E and F). In con-
trast, cells with RBP2 overexpression showed increased
mRNA and protein expression of VEGF as compared
with control transfection (Figure 2G-J). Histone H3K4
tri- and dimethylation was decreased with overexpres-
sion of RBP2 (Figure 2K and L).
Furthermore, to determine whether the regulation of
VEGF expression and angiogenesis coexisted with H3K4
demethylation of RBP2, we divided RBP2-targeted mu-
tant mice into mutant controls, heterozygotes and wild
types (Additional file 2: Figure S1) and examined VEGF
expression and MVD in gastric epithelia from the 3
groups. As compared with the wild type, mutant and
heterozygote groups showed inhibited VEGF expres-
sion and enhanced H3K4 trimethylation with RBP2
mutation (Figure 3A-E) as well as inhibited MVD as re-
vealed by CD31 and CD34 staining (Figure 3D and F).
The expression pattern for Ki67 was similar (Figure 3D
and E). Blockade of RBP2 demethylase activity may
have suppressed VEGF expression and impaired gastric
angiogenesis.
Transcriptional activation of VEGF expression in gastric
cancer cells by RBP2
Because VEGF expression was regulated by RBP2 at
both mRNA and protein levels, RBP2 might bind to the
promoter of VEGF directly. To determine whether
RBP2 regulated VEGF promoter activity, we cotrans-
fected pGL3-VEGF or pGL3-VEGF-mutant (Figure 4A)
into BGC-823, SGC-7901 and GES-1 cells with RBP2
siRNA or control siRNA and RBP2 expression vector or
control vector. Cotransfection with RBP2 expression
vector activated luciferase activity driven by the VEGF
promoter (Figure 4B). Conversely, inhibition of RBP2
expression decreased the luciferase activity driven by
the VEGF promoter. Mutations of the putative RBP2
binding site attenuated the change in luciferase activity
(Figure 4B and C). To determine whether VEGF was the
direct target of RBP2, we performed ChIP assay to de-
termine an association of RBP2 with the VEGF pro-
moter. In cells treated with control siRNA, RBP2
occupancy on the promoter region of VEGF gene was
readily detectable. In contrast, knocking down RBP2
abolished the association with this promoter sequence
(Figure 4D). Consistent with its H3K4 demethylase ac-
tivity, RBP2 depletion significantly enhanced H3-K4 tri-
methylation at the proximal promoter region of VEGF,
as documented in Figure 4D.
Figure 1 Association of RBP2 overexpression and increased VEGF expression in human gastric cancer. QRT-PCR analyses of (A) RBP2
mRNA and (B) VEGF mRNA in normal and cancerous human gastric tissues. *P < 0.05. (C) Correlation of RBP2 and VEGF levels in human gastric
cancer tissues after standardization with matched normal tissues. **P < 0.01. (D) Immunohistochemical staining of expression of RBP2, VEGF, CD31,
CD34 and Ki67 in human normal (left panel) and cancerous (right panel) gastric tissues. Representative images are shown. (E) Percentage positive
cells by immunohistochemistry for RBP2, VEGF and Ki67 in human normal and cancerous gastric tissues. **P < 0.01. (F) Percentage positive area
by immunohistochemistry for CD31 and CD34 in human normal and cancerous gastric tissues. **P < 0.01. Data are mean ± SEM of 3
independent experiments.
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Figure 2 The direct regulation of VEGF by RBP2 in human gastric cancer cells. QRT-PCR analyses of (A) RBP2 and (B) VEGF mRNA level in
control and RBP2 siRNA (10 nM)-transfected BGC-823, SGC-7901 and GES-1 cell lines after 72 h. **P < 0.01. Western blot analyses of (C, D) RBP2
and VEGF protein levels and (E, F) tri- and di- methylation of H3K4 in cancer cells treated with control and RBP2 siRNAs. C and R: Control and
RBP2 siRNA, respectively. **P < 0.01. QRT-PCR analyses of (G) RBP2 and (H) VEGF mRNA levels in cancer cells transfected with control and RBP2
expression vector (4 μg) after 48 h. **P < 0.01. (I, J) Western blot analyses of RBP2 and VEGF protein levels and (K, L) tri- and di- methylation of
H3K4 in cancer cells treated with control and RBP2 expression vectors. Vector C and R: Control pcDNA3.1 and pcDNA3.1-RBP2 expression
plasmids, respectively. **P < 0.01. Data are mean ± SEM of 3 independent experiments.
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tumorigenicity of human gastric cancer cell lines
We used western blot analysis to determine RBP2 and
VEGF expression in gastric cancer cells with RBP2 silen-
cing or VEGF overexpression (Figure 5A and B). Clone
formation assay was used to check the effect of RBP2 on
VEGF expression in tumorgenesis. RBP2 siRNA in BGC-
823, SGC-7901 and GES-1 significantly inhibited clone
formation. Cotransfection of RBP2 siRNA and VEGF ex-
pression vector reversed this inhibition in part (Figure 5C
and D).
The transfection of RBP2 expression vector markedly
increased the secretion of VEGF in BGC-823, SGC-7901
and GES-1 cell supernatant (Figure 5E) and RBP2 silen-
cing with RBP2 siRNA suppressed the VEGF secretion
(Additional file 3: Figure S2). Consistent with increased
expression of VEGF, the supernatants of BGC-823 and
GES-1 cells with RBP2 overexpression were more angio-
genic than those of control vector–transfected BGC-823
and GES-1 cells as determined by endothelial-cell tube-
formation assay (Figure 5F and G). These results suggest
the direct effect of RBP2 on VEGF expression in tumor-
genesis and angiogenesis.Regulation of VEGF expression, tumorgenesis and
angiogenesis by RBP2 in gastric tumors in nude mice
We established stable lentiviral-RBP2-shRNA–transfected
BGC-823 cells and injected them into the subcutis of
nude mice to evaluate the effect of knockdown of RBP2
expression on gastric tumor growth and angiogenesis by
regulating VEGF expression. In contrast with the large tu-
mors produced by control cells, RBP2-shRNA–trans-
fected BGC-823 cells produced much smaller gastric
tumors with slower growth (Figure 6A, B and C). To fur-
ther identify the mechanisms involved in RBP2-associated
gastric tumor growth, we examined the effect of RBP2 ex-
pression on VEGF expression and tumor angiogenesis in
nude mice. QRT-PCR and western blot analysis con-
firmed the silencing of RBP2 (Figure 6D, E and F). We
identified microvessel formation by immunostaining with
anti-CD31 and CD34 antibodies. Representative VEGF
expression and MVD in tumors with control and RBP2-
shRNA–transfected BGC-823 cells and quantification are
shown in Figure 6 G, H and I. In control mice, VEGF ex-
pression and microvessel formation was greater with
RBP2 overexpression than inhibition. These results sug-
gested that alteration of tumor growth and angiogenesis
Figure 3 (See legend on next page.)
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Figure 3 VEGF expression and angiogenesis in RBP2-targeted mutant mice. (A) QRT-PCR analysis of VEGF mRNA in the wild type (the
number is 6), heterozygote (4) and mutant mice (3). **P < 0.01 vs wild type group, ##P < 0.01 vs wild type group. (B, C) Trimethylation of H3K4 in
wild-type, heterozygote and mutant mice. Two representatives of each group are shown. **P < 0.01 vs wild type group, ##P < 0.01 vs wild type
group. (D) Hematoxylin and eosin (HE) staining and immunohistochemical staining of VEGF, CD31, CD34 and Ki67 expression in wild-type (left
panel), heterozygote (middle panel) and mutant mice (right panel). Representative images are shown. Percentage positive cells for (E) VEGF and
Ki67 and (F) percentage positive staining area for CD31 and CD34 in wild-type, heterozygote and mutant mice determined immunohistochemically.
**P < 0.01 vs wild type group, ##P < 0.01 vs wild type group. Data are mean ± SEM of 3 independent experiments.
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altered VEGF expression.
Discussion
In this study, we focused on the critical role of the his-
tone H3K4 demethylase RBP2 in angiogenesis of gastric
cancer, especially the direct regulation of VEGF by RBP2.Figure 4 Transactivation of VEGF promoter induced by RBP2. (A) Sche
mutant. (B) After transfection of RBP2 expression vector for 48 h, luciferase
vector and RBP2 siRNA cotransfection for 72 h as compared with control si
luciferase activity of VEGF promoter mutant reporters with RBP2 expression
trimethylation status of H3K4 at the promoter of the VEGF gene in BGC-82
mean ± SEM of 3 independent experiments.First, we determined the association of RBP2 expression,
VEGF expression and MVD status in human gastric can-
cer tissue species. Second, we detected the direct regula-
tion of VEGF by RBP2 both in human gastric cancer cell
lines and RBP2-targeted mutant mice, which showed that
H3K4 demethylation by RBP2 expression was important
for VEGF expression and MVD status. RBP2 bound tomatic structure of pGL3-VEGF promoter and pGL3-VEGF promoter
activity of VEGF promoter reporters as compared with the control
RNA. *P < 0.05 vs control vector. #P < 0.05 vs control siRNA. (C) The
vector and RBP2 siRNA cotransfection. (D) RBP2 occupancy and
3 cells. C and R: Control siRNA and RBP2 siRNA, respectively. Data are
Figure 5 (See legend on next page.)
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Figure 5 Promotion of tumorgenesis and angiogenesis by RBP2-induced VEGF expression in vitro. (A, B) Western blot analysis of RBP2
and VEGF protein levels in cancer cells treated with control and RBP2 siRNA or cotransfection of RBP2 siRNA and VEGF expression vector.
**P < 0.01 vs control, ##P < 0.01 vs RBP2 siRNA + pEGEP. (C) Foci formation of human gastric cancer cells after treatment with control and RBP2
siRNA or cotransfection of RBP2 siRNA and VEGF expression vector. (D) The foci numbers of clones. **P < 0.01 vs control. #P < 0.05 vs RBP2 siRNA +
pEGEP. (E) ELISA results for VEGF concentration in cell cultures treated with control vector and RBP2 expression vector. **P < 0.01. (F) Tube
formation in HUVEC cells treated with the supernatants from the cells transfected with control vector and RBP2 expression vector. (G) Tube
formation calculated as the percentage of cell surface area to the total surface area. The group incubated with the control cell cultures were set to
100%. **P < 0.01. Data are mean ± SEM of 3 independent experiments.
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moter of VEGF for regulation at the transcriptional level.
Third, VEGF expression induced by RBP2 overexpression
activated tumorigenesis and angiogenic potential in hu-
man gastric cancer cells and animal models, whereas
silencing of RBP2 expression had the reverse effect.
Therefore, abnormal RBP2 expression and VEGF activa-
tion might explain the poor prognosis with gastric cancer
and contribute directly to gastric tumor angiogenesis and
aggressive gastric cancer biology.
Angiogenesis is a critical process in the invasion, growth
and metastasis of most solid tumors [18]. Angiogenesis is
complex and involves a large number of molecules. VEGF,
fibroblast growth factor, angiopoietin, Notch, transforming
growth factor β, Hedgehog and WNT signaling cascades
orchestrate angiogenesis through the direct or indirect
regulation of quiescence, migration and the proliferation
of endothelial cells [19-23]. VEGF has critical roles in
tumor angiogenesis [24]. Small-molecule compounds and
human/humanized monoclonal antibodies interrupting
VEGF signaling have been developed as anti-angiogenic
therapeutics for cancer [25,26]. Epigenetic regulation in
angiogenesis is a new pathway in carcinogenesis and me-
tastasis. Lysine acetylation and cytosine methylation are
important transcriptional regulators of angiogenic genes
in endothelial cells. Lysine acetylation and cytosine methy-
lation inhibitors idiosyncratically tune the transcriptome
and affect expression of key modulators of angiogenesis
such as VEGF and endothelial nitric oxide synthase [27].
We have found that RBP2, a new histone H3K4
demethylase, is involved in carcinogenesis by escaping
cell senescene and inhibiting CDKIs [15,16]. In this re-
search, we first found RBP2 activation associated with
VEGF expression and tumorgenesis and angiogenesis in
human gastric cancer: RBP2 expression was positively
associated with VEGF mRNA and protein expression
and with MVD as identified by CD31 and CD34 anti-
body staining and cell proliferation by Ki67 overexpres-
sion, which suggests a link between RBP2 activation and
VEGF overexpression. RBP2 overexpression significantly
affected VEGF expression in gastric cancer cells via de-
methylation of H3K4. In RBP2-targeted mutant mice
with H3K4 demethylation of RBP2 silenced and H3K4
trimethylation enhanced, the expression of VEGF andthe aniogenic phenotype were also inhibited. As well,
RBP2 expression was involved in VEGF promoter activ-
ity in gastric cancer cells. Specifically, we identified one
potential RBP2 binding site on the VEGF promoter. Mu-
tation of the site profoundly attenuated but did not com-
pletely eliminate RBP2-mediated transactivation of the
VEGF promoter. Therefore, we confirmed by ChIP assay
that this binding site was functional, which showed ac-
tive recruitment of RBP2 to the binding site.
H3-K4 methylation is associated with transcription ac-
tivation [28-30]. As a histone demethylase specific for di-
and tri-methylated H3-K4, RBP2 acts as a transcriptional
repressor by inhibiting H3-K4 methylation at its target
promoters [31,32]. However, we found that VEGF was a
direct target of RBP2. Not as the suppression of CDKIs
promoters by RBP2 in gastric cancer, RBP2 induced the
activation of VEGF promoter by directly binding to the
CCGCCC DNA motif [33]. Another important H3K4
demethylase, LSD1, which is overexpressed in numerous
cancers, was found involved in inducing VEGF expres-
sion in prostate cancer [34]. LSD1 was also identified to
act through its demethylase activity to promote epigen-
etic modifications at Notch-target genes. Remarkably,
LSD1 functions as a corepressor when associated with
the CSL-repressor complex and as a NOTCH1 coactiva-
tor upon Notch activation [35]. In addition, RBP2 is
present in a number of chromatin-remodeling complexes
[36,37]. Polycomb-repressive complex 2 recruits RBP2 to
its target genes via physical interaction [32]. This situ-
ation may occur with the promoter of the VEGF gene.
However, we need more evidence to determine whether
RBP2 affects the VEGF promoter methylation status,
which is involved in the regulation of VEGF expression
[9] in human gastric cancer cells.
We detected the critical role of RBP2 in angiogenesis
by the biological effect in human cancer cells and animal
models. With RBP2 siRNA, RBP2 expression was si-
lenced and VEGF expression inhibited. The clone forma-
tion of human gastric cancer cells was also suppressed
in this process, which was partially reversed by the over-
expression of VEGF in RBP2 siRNA-transfected cells.
We found RBP2 involved in gastric carcinogenesis by
the regulation of VEGF. In nude mice, tumors from
transfected gastric cancer cells stably expressing RBP2
Figure 6 (See legend on next page.)
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Figure 6 Inhibition of VEGF expression and angiogenesis by RBP2 knockdown in nude mice. (A) Tumorgenesis after injection of BGC-823
cells stably expressing RBP2 shRNA and control shRNA. (B) Tumor volume with RBP2 shRNA stable expression and controls. Data are median, with
box edges as interquartile range and whiskers as the minimum and maximum values. **P < 0.01. (C) Growth curve with RBP2 shRNA stable
expression and controls. **P < 0.01. (D) QRT-PCR analysis of RBP2 mRNA expression with RBP2 shRNA stable expression and controls. **P < 0.01
(E, F) Western blot analysis of RBP2 protein expression with RBP2 shRNA stable expression and the control. **P < 0.01. (G) Immunohistochemical
staining for VEGF, CD31, CD34 and Ki67 in the control group (left panel) and RBP2 shRNA stable expression group (right panel). Representative
images are shown. (H) Percentage positive area for CD31 and CD34 expression with the control and RBP2 shRNA stable expression determined
immunohistochemically. **P < 0.01. (I) Percentage positive cells for VEGF and Ki67 with the control and RBP2 shRNA stable expression determined
immunohistochemically. **P < 0.01.
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less MVD and cell proliferation than control cells. Recent
genome-wide analyses of mouse embryonic stem cells and
human leukemic cell lines revealed hundreds of RBP2 tar-
get genes and many of them implicated in development,
proliferation and differentiation controls [32,38,39]. RBP2
was identified as a key molecule in drug tolerance of can-
cer cells and maintaining cancer stem cells [40,41]. Our
new findings that RBP2 is critical in constitutive and indu-
cible VEGF expression might suggest its clinical implica-
tion in gastric tumor angiogenesis and progression.
Surgery plays a central role in the overall management
of operable gastric cancer. Histone deacetylase inhibi-
tors, based on epigenetic development, are being used
clinically [42], and histone demethylase inhibitors are
being addressed in clinical trials [43]. Our study identi-
fied a novel molecular mechanism for RBP2 and pro-
vides better understanding of the molecular basis for
angiogenetic signaling pathways, which might aid in the
design of effective therapeutic modalities to control gas-
tric cancer growth and metastasis.
Conclusions
In this study, we detected the regulation of VEGF by
H3K4 demethylase RBP2 directly in vivo and in vitro.
This regulation plays an important role in tumorgenesis
and angiogenesis of human gastric cancer. RBP2 may be
critical in cancer angiogenesis.
Materials and methods
Patients and tissue specimens
Resected pairs of human gastric cancer tissue and distal
normal gastric tissue (>5 cm from the margin of the
tumor) from 27 patients were harvested during surgery at
Qilu Hospital of Shandong University in 2013. No patient
had received adjuvant chemotherapy before surgery. The
diagnosis of gastric cancer was confirmed histopathologic-
ally. The general information for patients is in Additional
file 1: Table S1. The study was approved by the ethics
committee of Shandong University School of Medicine.
Immunohistochemistry
Tissues from human resected pairs and animal models
were embedded with paraffin and sliced into 5-μm pieces,which were deparaffinized and dehydrated with xylene
and a graded series of alcohol. Antigen retrieval involved
heat treatment performed in 0.1 M citrate buffer at
pH 6.0. Then 3% H2O2 was used to block endogenous
peroxidase activity. The slides were further incubated
with goat serum for 30 min, then with the antibodies
monoclonal rabbit anti-human RBP2 (Sigma, USA); poly-
clonal rabbit anti-VEGF, anti-CD31, and anti-Ki67 (all
Abcam, UK); and monoclonal mouse anti-CD34 (Santa
Cruz Biotechnology, USA) overnight at 4°C. The results
were detected with diaminobenzidine staining (Vector
Laboratories, USA) under a microscope (Olympus BX60,
Tokyo) and images were captured for analysis.Cell lines and culture
The gastric epithelial-derived cancer cell lines BGC-823
and SGC-7901 were obtained from the cell repository for
Academia Sinica (Shanghai). Human gastric epithelial
immortalized GES-1 cells were maintained in our labora-
tory. All cell lines were grown in RPMI1640 medium
(Gibco, USA) supplemented with 10% fetal bovine serum
(Gibco, USA). Cell lines were incubated in a humidified
atmosphere containing 5% CO2 at 37°C without antibi-
otics, then cultured on 6-well plates for 18 to 24 h before
experiments.RNA extraction and quantitative RT-PCR
The total RNA in human or animal samples and cell lines
was extracted by use of Trizol (Invitrogen, Life technolo-
gies, USA). cDNA was synthesized with use of MMLV re-
verse transcriptase (Fermentas, Canada). The expression of
genes was checked by PCR with the TaqMan gene expres-
sion assay kit (Life Technologies, USA) or SYBR Premix
Ex Taq kit (Takara, Dalian) with β-actin as a control.
Real-time PCR involved the ABI7500 sequence detector
(Applied Biosystems, USA). The assay IDs for human
resected tissues and cell lines were RBP2, Hs00188160_m1;
and VEGF, Hs00900055_m1. The PCR primers for VEGF
expression in mice were sense, 5'-CTGTACCTCCACC
ATGCCAAGT-3', and antisense, 5'-CTTCGCTGGTAGAC
ATCCATGA-3'. RBP2 and VEGF mRNA expression was
normalized to β-actin expression. Change in expression
was calculated relative to the control (2-ΔΔCt).
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assay (ELISA)
Total cellular proteins were extracted with RIPA lysis
buffer. The membranes were probed with antibodies
against RBP2 (Abcam, UK) and VEGF followed by
anti- rabbit horseradish peroxidase-conjugated immuno-
globulin G and developed by the enhanced chemilu-
mines- cent method (PIERCE, Thermo Fisher Scientific,
USA). β-actin was a loading control. For immunoblot-
ting of histone H3-K4 di- and trimethylation, we isolated
a total histone fraction from nuclei using dilute acid ex-
traction Zeng J et al., [15]. Histone proteins were de-
tected with antibodies against di- and trimethylated H3-
K4 (Abcam, UK). H3 was the control. An ELISA kit
(R&D Systems, USA) was used for quantification of hu-
man VEGF secretion in cell culture supernatants.
Promoter activity assay
The promoter sequence of VEGF was obtained from 2
databases, TRED and GENECARDS. The primer se-
quences for VEGF promoter amplification were sense, 5'-
GGTACCTGTGAGCCTGGAGAAGTAGCC-3' (KpnI),
and antisense, 5'-AAGCTTACAGTGATTTGGGGAAG
TAGAGC-3' (HindIII). The result was detected by se-
quencing. The VEGF promoter sequence was cloned into
pGL3-Basic Vector, named pGL3-VEGF. The mutation of
the RBP2 binding site (CCGCCC) in the VEGF promoter
sequence was preceded by PCR. The primers for mutation
were sense, 5'- TGGTGGATTATAGTGGAGG -3', and
antisense, 5'- CCTCCACTATAATCCACCAG -3'. The se-
quence was cloned into the plasmid, named pGL3-VEGF-
mutant. The RBP2 expression vector and RBP2 siRNA
were transfected into cells with the promoter reporter
plasmids for VEGF. The Renilla luciferase-containing plas-
mid controlled by the thymidine kinase (TK) promoter
was co-transfected as a control. Luciferase activity in the
cell lysates was determined by dual luciferase reporter
assay (Promega, USA) at 48 h after transfection, and the
target promoter-driven firefly luciferase activity was nor-
malized to that of TK renilla.
Chromatin immunoprecipitation (ChIP)
Control and RBP2 siRNA-treated BGC-823 cells were
cross-linked by incubation in 1% formaldehyde-containing
medium for 10 min at 37°C and then sonicated to make
soluble chromatin with DNA fragments between 200 and
1000 bp. Antibodies against RBP2 and tri- or di- methyl-
ated H3-K4 were used to precipitate DNA fragments
bound by their corresponding elements. The protein–
DNA complex was collected with protein A Sepharose
beads (Millipore), eluted, and reverse cross-linked. Follow-
ing treatment with protease K (Sigma-Aldrich), samples
were extracted with phenol-chloroform and precipitated
with ethanol. The recovered DNA was resuspended in TEbuffer and used for PCR amplification. The PCR primers
were for the VEGF promoter, sense, 5'- GGCGGGTAGG
TTTGAATC -3', and antisense, 5'- CGTATGCACTGTG
GAGTC -3'; and GAPDH, sense, 5'- AAAGGGCCCTGA
CAACTCTT -3', and antisense, 5'- GGTGGTCCAGGG
GTCTTACT -3', as a control.
Colony-formation assay
Cells were incubated in 6-well plates for 18 to 24 h, then
transfected with the corresponding vectors for 48 h or
different siRNAs for 72 h. Single cells were seeded on 6-
well plates (500 cells/well). After 10 to 14 days of incu-
bation with 2% fetal bovine serum, plates were stained
with Giemsa for 20 min. Colonies with more than 50
cells were counted.
Endothelial-cell tube-formation assay
The tube-formation assay was described previously Gong
W et al., [44]. Briefly, 250 μL of growth factor-reduced
Matrigel (BD Biosciences, USA) was pipetted into each
well of a 24-well plate and polymerized for 30 min at
37°C. Human umbilical vein endothelial cells were har-
vested after trypsin treatment and suspended in condi-
tioned medium from 1 × 106 BGC-823 and GES-1-RBP2
overexpression cells or 1 × 106 BGC-823 and GES-1-
control cells cultured for 48 h in Dulbecco modified
Eagle medium containing 1% fetal bovine serum. Then
2 × 104 human umbilical vein endothelial cells in 300 μL
conditioned medium were added to each well and incu-
bated at 37°C, 5% CO2, for 20 h. The cultures were
photographed by microscopy. The degree of tube forma-
tion was assessed as the percentage of cell surface area to
total surface area. Control cell cultures values were set at
100%.
Animal models
BGC-823 cells stably expressing RBP2 shRNA to inhibit
RBP2 expression and matched controls were constructed.
A total of 10 BALB/c nude mice 7 weeks old (Vital River
Laboratories, P.R.China) were divided into 2 groups ran-
domly. BGC-823 cells with RBP2 shRNA or the matched
control were subcutaneously injected into mice (2 × 105
cells/mouse). 15 days later, tumors were harvested and
tumor size measured. Tumor volume was calculated as
greatest tumor diameter × (shortest tumor diameter)2/2.
RBP2-targeted mutant mice were provided by the Jack-
son Laboratory [strain B6.129S6(FVB)-Kdm5atm1.1Kael/J].
The genotypes of mice were determined by protocols
from the Jackson Laboratory. The primers used for PCR
were for the wild type, forward, 5'- GTTTGAATTTCAC
TCTATGCTGGG -3'; mutant forward, 5'- GGTGCTGG
GAACCATACTTG -3'; and common, 5'- TCCCAGC
ATGGATCTTGTCC -3'. The PCR results showed differ-
ent genotypes: mutant = 530 bp, heterozygote = 216 and
Li et al. Molecular Cancer 2014, 13:81 Page 12 of 13
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cols were approved by the local Animal Care and Use
Committee.
Statistical analysis
Quantitative data are expressed as mean ± SEM. Statis-
tical analysis involved use of SPSS 13.0 (SPSS Inc., USA)
with two-tailed Student's t test or one-way ANOVA for
more than 2 subgroups. Statistical significance was set at
P < 0.05.
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Additional file 2: Figure S2. RT-PCR results of RBP2-targeted mutant
mice.
Additional file 3: Figure S3. ELISA results for VEGF concentration in
the cell cultures treated with control siRNA and RBP2 siRNA.
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